May 13, 2026
Chondroitin Sulfate Sourcing in 2026: What 240 Million Osteoarthritis Patients Mean For Supply
Osteoarthritis affects over 240 million people worldwide. And the number of people over 60 is set to double by 2050. Here's what that means for the chondroit...
-
![Have Small-Molecule Weight-Loss Drugs Reached A Dead End?]()
Sep 15, 2025Have Small-Molecule Weight-Loss Drugs Reached A Dead End?GLP-1 receptor agonists have garnered widespread attention due to their remarkable weight-loss and diabetes-treatment effects. However, despite the...view more -
![Nanjing Tech University Achieves High-Yield Ectoine Production By E. Coli U...]()
Sep 09, 2025Nanjing Tech University Achieves High-Yield Ectoine Production By E. Coli U...Ectoine ( 1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid , CAS: 96702-03-3 ), a natural protective molecule, exhibits an exceptional ...view more -
![Aikang Biopharma’s Breakthrough First: Driving The 'Gold Rush' Of PD-1/VEGF ...]()
Sep 08, 2025Aikang Biopharma’s Breakthrough First: Driving The 'Gold Rush' Of PD-1/VEGF ...Aikang Biopharma's Breakthrough First Introduction: Sparking the "Gold Rush" of PD-1/VEGF Bispecific Antibodies In the evolution of immuno-onc...view more -
![€3.8 Billion Bet: Servier Acquires Global Rights (Ex-US) To PKC Inhibitor D...]()
Sep 05, 2025€3.8 Billion Bet: Servier Acquires Global Rights (Ex-US) To PKC Inhibitor D...Introduction: Servier secures worldwide (excluding the US) rights to the PKC inhibitor darovasertib in a major deal.view more -
![Over $5 Billion Deal: MNCs Snap Up Domestic Innovative Drugs Again]()
Sep 05, 2025Over $5 Billion Deal: MNCs Snap Up Domestic Innovative Drugs AgainIntroduction: Involving Multiple Cardiovascular siRNA Therapeuticsview more -
![Pfizer’s Key Drug For Sickle Cell Disease, Inclacumab, Fails To Meet Primary ...]()
Aug 21, 2025Pfizer’s Key Drug For Sickle Cell Disease, Inclacumab, Fails To Meet Primary ...Recently, Pfizer announced that its investigational key drug for sickle cell disease (SCD), inclacumab, failed to meet the primary endpoint in the ...view more -
![Oral TXA Doesn’t Darken Or Lighten Hair: Study]()
Aug 19, 2025Oral TXA Doesn’t Darken Or Lighten Hair: StudyTranexamic acid (TXA) is widely used to treat melasma, but its potential effects on hair pigmentation have remained unexplored. Concerns about hair...view more -
![Bayer's Latest Move Worth 9.3 Billion Yuan]()
Aug 15, 2025Bayer's Latest Move Worth 9.3 Billion YuanOn August 12th, Bayer and biotech company Kumquat Biosciences announced the achievement of a global exclusive licensing and collaboration agreement...view more -
![Novartis' Major New Drug Achieves Positive Phase III Results]()
Aug 14, 2025Novartis' Major New Drug Achieves Positive Phase III ResultsOn August 11th, Novartis announced that its anti-BAFF-R monoclonal antibody Ianalumab (VAY736) met the primary endpoints in two Phase III clinical ...view more -
![WHO Declares Hepatitis D As Carcinogenic,Urging Urgent Action To Combat Hepat...]()
Aug 13, 2025WHO Declares Hepatitis D As Carcinogenic,Urging Urgent Action To Combat Hepat...On World Hepatitis Day, WHO calls on governments and partners to urgently step up efforts to eliminate viral hepatitis as a public health threat an...view more -
![Termination Of The Cooperation Agreement With Bicycle Therapeutics]()
Aug 13, 2025Termination Of The Cooperation Agreement With Bicycle TherapeuticsRecently, Genentech, a subsidiary of Roche, announced the termination of its cooperation agreement with Bicycle Therapeutics, and this decision wil...view more -
![Merck Ranks 2nd in Global Pharma AI Maturity Index – Driving AI Innovation Ac...]()
Aug 12, 2025Merck Ranks 2nd in Global Pharma AI Maturity Index – Driving AI Innovation Ac...CB Insights has released its Global Top 50 Pharma AI Maturity Index, and Merck secures the 2nd position, showcasing exceptional strength in AI acro...view more
